Compumedics (ASX:CMP) secured multiple Somfit sales to US-based pharmaceutical contract research organization and Finland-based Orion Pharma, with nearly $2 million of combined revenues from initial transactions, according to a Monday filing with the Australian bourse.

Somfit is a wearable home sleep test device designed to help diagnose sleep-related breathing disorders.

The first transaction involved a clinical drug trial facilitated by the contract research organization in the US, and the second involved the deployment of Somfit in a multi-country, multi-center clinical study across Europe, the filing said.

Shares fell more than 1% in midday trade Monday.